Zou Xinmei, Wang Yang
Ward 13 (Respiratory Digestive Geriatrics), Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, China.
Front Med (Lausanne). 2025 May 1;12:1527829. doi: 10.3389/fmed.2025.1527829. eCollection 2025.
Early detection, systematic prevention, and personalized therapy are crucial to reduce mortality in patients with gastrointestinal (GI) cancers. This systematic review and meta-analysis aimed to clarify the predictive value of osteopenia and osteosarcopenia as prognostic markers of survival and recurrence in patients with GI cancers.
Medline, Google Scholar, and Science Direct databases were searched for English-language studies that included patients who underwent surgical resection following a pathologically diagnosed GI cancer and reported the association between osteopenia and osteosarcopenia on the overall survival (OS) and recurrence-free survival (RFS). Meta-analysis was done using STATA 14.2, and the results were reported as pooled hazard ratios (HR) with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic and the Chi-square test. Study quality was evaluated using the Newcastle Ottawa Scale (NOS).
A comprehensive literature search yielded 23 eligible studies, primarily from Japan. Osteopenia emerged as a significant risk factor for both OS (pooled HR 2.20, 95% CI: 1.74-2.79) and RFS (pooled HR 2.15, 95% CI: 1.60-2.89). Patients with osteosarcopenia exhibited threefold higher mortality rates (pooled HR 2.96, 95% CI: 1.99-4.40) and heightened risk of recurrence (pooled HR 2.75, 95% CI: 1.79-4.24). Subgroup analyses underscored the consistency of these associations across diverse contexts.
This meta-analysis establishes osteopenia and osteosarcopenia as robust prognostic indicators for survival and recurrence in GI cancers. Integrating musculoskeletal assessments into routine oncological care is imperative for timely interventions and optimized patient outcomes.
早期检测、系统预防和个性化治疗对于降低胃肠道(GI)癌症患者的死亡率至关重要。本系统评价和荟萃分析旨在阐明骨质减少和骨质疏松症作为GI癌症患者生存和复发的预后标志物的预测价值。
在Medline、谷歌学术和科学直投数据库中检索英文研究,这些研究纳入了经病理诊断为GI癌症后接受手术切除的患者,并报告了骨质减少和骨质疏松症与总生存期(OS)和无复发生存期(RFS)之间的关联。使用STATA 14.2进行荟萃分析,结果报告为合并风险比(HR)及95%置信区间(CI)。使用I2统计量和卡方检验评估异质性。使用纽卡斯尔渥太华量表(NOS)评估研究质量。
全面的文献检索产生了23项符合条件的研究,主要来自日本。骨质减少成为OS(合并HR 2.20,95%CI:1.74 - 2.79)和RFS(合并HR 2.15,95%CI:1.60 - 2.89)的显著危险因素。患有骨质疏松症的患者死亡率高出三倍(合并HR 2.96,95%CI:1.99 - 4.40),复发风险增加(合并HR 2.75,95%CI:1.79 - 4.24)。亚组分析强调了这些关联在不同背景下的一致性。
本荟萃分析确定骨质减少和骨质疏松症是GI癌症生存和复发的有力预后指标。将肌肉骨骼评估纳入常规肿瘤护理对于及时干预和优化患者结局至关重要。